Evidence map›Paper›PMID 36306520›Full record

Trial reportAIDS patient care and STDs2022

Validation of HIV Pre-Exposure Prophylaxis (PrEP) Medication Scales with Youth on PrEP: PrEP Confidence Scale and PrEP Difficulties Scale.

Henna Budhwani, Ibrahim Yigit, Allysha C Maragh-Bass, Crissi B Rainer, Kristina Claude, Kathryn E Muessig, Lisa B Hightow-Weidman

Abstract readClinical Trial
In one paragraph

Trial report in AIDS patient care and STDs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Validation of the PrEP Use Self-Efficacy (PrEP-Use) Scale Among Sexual Minority Men.AIDS education and prevention : official publication of the International Society for AIDS Education · 2025
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Identifying Key Factors to PrEP Initiation and Persistence Among YMSM Through Focus Groups and Surveys in Two High-Priority Settings.AIDS education and prevention : official publication of the International Society for AIDS Education · 2024
    Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Henna BudhwaniCenter of Population Sciences for Health Equity, College of Nursing, Florida States University (FSU), Tallahassee, Florida, USA.ORCID 0000-0002-6716-9754
Ibrahim YigitDepartment of Psychology, Faculty of Arts and Sciences, TED University, Ankara, Turkey.
Allysha C Maragh-BassBehavioral, Epidemiological, Clinical Sciences Division, Durham, North Carolina, USA.
Crissi B RainerInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill (UNC), Chapel Hill, North Carolina, USA.
Kristina ClaudeInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill (UNC), Chapel Hill, North Carolina, USA.
Kathryn E MuessigGillings School of Global Public Health, University of North Carolina at Chapel Hill (UNC), Chapel Hill, North Carolina, USA.
Lisa B Hightow-WeidmanInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill (UNC), Chapel Hill, North Carolina, USA.

Funding

The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuumU19HD089881 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIGHTOW-WEIDMAN, LISA B, SULLIVAN, PATRICK SEAN · 2016 to 2022
$35.8M
Training Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4M
COVID-19 Administrative Supplement to K01: Adapting, Pilot Testing a Behavioral Intervention to Incorporate Advances in HIV Prevention for Black Young MSM in AlabamaK01MH116737 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUDHWANI, HENNA · 2019 to 2023
$899k
NICHD NIH HHS U19 HD089881NIMH NIH HHS K01 MH116737NIMH NIH HHS R25 MH067127
6 · The paper itself

Abstract

Pre-exposure prophylaxis (PrEP) is a lifesaving medical intervention that protects against human immunodeficiency virus (HIV), but to date, PrEP uptake has been limited. PrEP utilization and adherence among youth, including stigmatized and highly vulnerable young sexual and gender minorities, have been exceptionally low across all regions, leading to preventable HIV transmission. Considering the scientific value of measuring and understanding predictors or associations of PrEP adherence, our study team validated two scales: a PrEP Difficulties Scale and a PrEP Confidence Scale tested within the Adolescent Trials Network P3 study (2019-2021). Data from sexual and gender minorities who were prescribed PrEP across nine domestic sites were evaluated (

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesAdolescentHomosexuality, MaleHumansMaleSocial StigmaAnti-HIV AgentsconfidencedifficultiesdisclosureHIVpre-exposure prophylaxisPrEPscale developmentscale validationself-efficacy

Identifiers

PMID36306520
PMCPMC9700336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.